The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction

Gacci, Mauro; Salvi, Matteo; Sebastianelli, Arcangelo; Vignozzi, Linda; Corona, Giovanni; McVary, Kevin T.; Kaplan, Steven A.; Maggi, Mario; Carini, Marco; Oelke, Matthias
April 2013
Research & Reports in Urology;Apr2013, Vol. 5, p99
Academic Journal
A strong and independent association between lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and erectile dysfunction (ED) has been widely evidenced in several clinical epidemiologic studies. Preclinical animal models have provided a great deal of information on potential common pathogenic mechanisms underlying these two clinical identities. Although the efficacy of the most commonly used treatments for LUTS/BPH is well defined, the negative impact of these treatments on sexual function -- in particular, on ED -- has triggered the search for new treatment options. In this regard, a new role for phosphodiesterase type 5 inhibitors in the treatment of LUTS/BPH and ED has been claimed. Tadalafil is one of the most extensively investigated phosphodiesterase type 5 inhibitors for this new indication. All evidence reported to date suggests that tadalafil 5 mg once daily is a safe and effective treatment option for both LUTS/BPH and ED.


Related Articles

  • Tadalafil.  // AHFS Consumer Medication Information;Aug2020, p1 

    Tadalafil (Cialis) is used to treat erectile dysfunction (ED, impotence; inability to get or keep an erection), and the symptoms of benign prostatic hyperplasia (BPH; an enlarged prostate) which include difficulty urinating (hesitation, dribbling, weak stream, and incomplete bladder emptying),...

  • Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations. Alsaikhan, Bader; Alrabeeah, Khalid; Carrier, Serge // International Journal of General Medicine;2014, Vol. 7, p271 

    Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age. Several studies have identified a true association between these two disorders. Basic research studies have shown a significant decrease in the nitric oxide/cyclic guanosine monophosphate pathway with age that leads...

  • Tadalafil Monotherapy for Benign Prostatic Hyperplasia. Gacci, M. // Urologia Internationalis;Nov2013, Vol. 91 Issue 4, p487 

    No abstract available Copyright © 2012 S. Karger AG, Basel

  • Erectile dysfunction drug approved to treat BPH symptoms.  // Mayo Clinic Health Letter;Apr2012, Vol. 30 Issue 4, p4 

    The article reports that the U.S. Food and Drug Administration has approved tadalafil (Cialis) as a drug for the treatment of urinary symptoms of benign prostatic hyperplasia (BHP).

  • New Pharmacologic Horizons in the Treatment of Benign Prostatic Hyperplasia. Kojima, Yoshiyuki; Hayase, Masa; Sasaki, Shoichi; Hayashi, Yutaro; Kohri, Kenjiro // Current Drug Therapy;Nov2010, Vol. 5 Issue 4, p262 

    Benign prostatic hyperplasia (BPH) is a progressive disease that is commonly associated with bothersome lower urinary tract symptoms (LUTS) such as incomplete emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Surgical therapy, mainly transurethral resection of the...

  • Update on medical therapy for male LUTS. Radomski, Sidney B. // Canadian Urological Association Journal;jui/aou2014 supplement 5, Vol. 8, pS148 

    The medical management of lower urinary tract symptoms (LUTS) is aimed at addressing voiding and storage symptoms in patients with benign prostate hyperplasia (BPH) symptoms with or without an overactive bladder (OAB). Current available options for BPH include alpha-blockers, 5-alpha reductase...

  • Medical Treatment Options for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. Gravas, Stavros // Current Medical Literature: Urology;2012, Vol. 18 Issue 4, p97 

    The article presents information on therapies for patients suffering from lower urinary tract symptoms and benign prostatic hyperplasia. It explains that a systematic diagnostic evaluation can be done by taking a patient's history, validated symptom questionnaires and a bladder diary in cases of...

  • PDE-5 inhibitors, antimuscarinics may play a role in BPH. Overmyer, Mac // Urology Times;8/15/2006, Vol. 34 Issue 10, p12 

    The article discusses several studies on the significance of drugs indicated for other urologic conditions for the treatment of urinary tract symptoms in men with benign prostatic hyperplasia (BPH). Several researchers discovered that phosphodiesterase type-5 inhibitors are effective for the...

  • Tadalafil Improves BPH/LUTS.  // Renal & Urology News;Sep2013, Vol. 12 Issue 9, p17 

    The article offers information on the meta-analysis conducted by Chinese investigators which shows the efficacy of a phosphodiesterase type 5 inhibitor Tadalafil in relieving lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics